Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

The iShares U.S. Pharmaceuticals ETF (IHE) has outperformed most healthcare benchmarks over the past year despite public threats from the U.S. President, highlighting resilience in the pharma trade. The article is mainly a performance and sentiment note rather than a catalyst-driven update, with the key takeaway being continued relative strength amid political pressure.

Analysis

The iShares U.S. Pharmaceuticals ETF (IHE) has outperformed most healthcare benchmarks over the past year despite public threats from the U.S. President, highlighting resilience in the pharma trade. The article is mainly a performance and sentiment note rather than a catalyst-driven update, with the key takeaway being continued relative strength amid political pressure.